CYTK Stock Summary and Trading Ideas (Cytokinetics | NASDAQ:CYTK)

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics trades on the NASDAQ stock market under the symbol CYTK.

As of September 25, 2026, CYTK stock price declined to $64.66 with 1,518,934 million shares trading.

CYTK has a beta of 0.73, meaning it tends to be less sensitive to market movements. CYTK has a correlation of 0.05 to the broad based SPY ETF.

CYTK has a market cap of $8.99 billion. This is considered a Mid Cap stock.

Last quarter Cytokinetics reported $29 million in Revenue and -$1.50 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.12.

In the last 3 years, CYTK traded as high as $110.25 and as low as $25.98.

The top ETF exchange traded funds that CYTK belongs to (by Net Assets): IJH, VTI, IWM, VB, XBI.

CYTK has outperformed the market in the last year with a return of +33.9%, while the SPY ETF gained +17.8%. However, in the most recent history, CYTK shares have underperformed the stock market with its stock returning -20.4% in the last 3 month period and -12.2% for the last 2 week period, while SPY has returned +5.5% and +2.0%, respectively.

CYTK support price is $63.95 and resistance is $67.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYTK shares will trade within this expected range on the day.